Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Operating Margin (2020 - 2024)

Barinthus Biotherapeutics filings provide 5 years of Operating Margin readings, the most recent being 62.66% for Q3 2024.

  • On a quarterly basis, Operating Margin changed N/A to 62.66% in Q3 2024 year-over-year; TTM through Dec 2025 was 471.34%, a 1727.0% decrease, with the full-year FY2024 number at 454.07%, up 1000902.0% from a year prior.
  • Operating Margin hit 62.66% in Q3 2024 for Barinthus Biotherapeutics, up from 7885.33% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 1666800.0% in Q4 2021 to a low of 48128.57% in Q2 2021.
  • Median Operating Margin over the past 5 years was 659.43% (2020), compared with a mean of 104644.19%.
  • Biggest five-year swings in Operating Margin: skyrocketed 166952119bps in 2021 and later plummeted -166718862bps in 2022.
  • Barinthus Biotherapeutics' Operating Margin stood at 2721.19% in 2020, then surged by 61353bps to 1666800.0% in 2021, then crashed by -100bps to 388.62% in 2022, then plummeted by -1929bps to 7885.33% in 2023, then skyrocketed by 99bps to 62.66% in 2024.
  • The last three reported values for Operating Margin were 62.66% (Q3 2024), 7885.33% (Q2 2023), and 4590.6% (Q1 2023) per Business Quant data.